Exploiting collateral sensitivity controls growth of mixed culture of sensitive and resistant cells and decreases selection for resistant cells in a cell line model

Exploiting collateral sensitivity controls growth of mixed culture of sensitive and resistant cells and decreases selection for resistant cells in a cell line model

Abstract Background CDK4/6 inhibitors such as ribociclib are becoming widely used targeted therapies in hormone-receptor-positive (HR+) human epidermal growth factor receptor 2-negative (HER2−) breast cancer. However, cancers can advance due to drug resistance, a problem in which tumor heterogeneity...

Full description

Bibliographic Details
Main Authors: Vince Kornél Grolmusz, Jinfeng Chen, Rena Emond, Patrick A. Cosgrove, Lance Pflieger, Aritro Nath, Philip J. Moos, Andrea H. Bild
Format: Article
Language:English
Published: BMC 2020-06-01
Series:Cancer Cell International
Subjects:
Collateral sensitivity
Tumor heterogeneity
Drug resistance
CDK4/6 inhibitor
Wee-1-inhibitor
Online Access:http://link.springer.com/article/10.1186/s12935-020-01337-1

Internet

http://link.springer.com/article/10.1186/s12935-020-01337-1

Similar Items